The United States reached a deal for up to $2.1 billion with pharmaceutical firms Sanofi and GlaxoSmithKline, for the development and (if it is effective) production of up to 100 million doses of a potential COVID-19 vaccine, based on proteins found on SARS-CoV-2. Sanofi’s effort is now a part of Operation Warp Speed, joining the Pfizer-BioNTech, AstraZeneca-University of Oxford, and Novavax Inc. vaccines, as well as the Regeneron antibody treatment.
U.S. and Canada Public
Another Vaccine Candidate Joins Operation Warp Speed
About the author
Latest articles
Related coverage
-
Strategic War Danger Paid
AI in Targeting Does Not Reduce Civilian Casualties
-
Strategic War Danger Paid
Army War College Lunatics Label Contacts with Chinese People a 'Strategic Threat'
-
U.S. and Canada Paid
Dems Need To Be Pressured To Get Any Change
-
Collapsing Imperial System
Administration Plays Down the Dismal Week for U.S. Infrastructure